These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29335263)

  • 21. [Psychoses in patients with Parkinson's disease; their frequency, phenomenology, and clinical correlates].
    Kashihara K; Ohno M; Katsu Y
    Rinsho Shinkeigaku; 2005 Jan; 45(1):1-5. PubMed ID: 15714992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of neurotransmitters in the development of Parkinson's disease-related psychosis.
    Factor SA; McDonald WM; Goldstein FC
    Eur J Neurol; 2017 Oct; 24(10):1244-1254. PubMed ID: 28758318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human Laboratory Studies on Cannabinoids and Psychosis.
    Sherif M; Radhakrishnan R; D'Souza DC; Ranganathan M
    Biol Psychiatry; 2016 Apr; 79(7):526-38. PubMed ID: 26970363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-Rank Symptoms in Methamphetamine Psychosis and Schizophrenia.
    Shelly J; Uhlmann A; Sinclair H; Howells FM; Sibeko G; Wilson D; Stein DJ; Temmingh H
    Psychopathology; 2016; 49(6):429-435. PubMed ID: 27926911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cannabis-Induced Psychosis and an Antipsychotic-Induced Seizure: A Case Report.
    Perera T; Webler R
    Prim Care Companion CNS Disord; 2017 Feb; 19(1):. PubMed ID: 28157276
    [No Abstract]   [Full Text] [Related]  

  • 26. Cognitive correlates of hallucinations and delusions in Parkinson's disease.
    Factor SA; Scullin MK; Sollinger AB; Land JO; Wood-Siverio C; Zanders L; Freeman A; Bliwise DL; McDonald WM; Goldstein FC
    J Neurol Sci; 2014 Dec; 347(1-2):316-21. PubMed ID: 25466695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance of the scale for assessment of positive symptoms in Parkinson's disease psychosis.
    Voss TS; Brocht AF; Ravina B
    Mov Disord; 2010 Jan; 25(1):124-5. PubMed ID: 19412941
    [No Abstract]   [Full Text] [Related]  

  • 28. [Acute Psychosis after Consumption of Synthetic Cannabinoids].
    Mörkl S; Blesl C; Wurm WE; Tmava A
    Fortschr Neurol Psychiatr; 2016 Mar; 84(3):150-4. PubMed ID: 27029042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pimavanserin approved for Parkinson's-related hallucinations, delusions.
    Traynor K
    Am J Health Syst Pharm; 2016 Jun; 73(12):853. PubMed ID: 27261226
    [No Abstract]   [Full Text] [Related]  

  • 30. Cannabinoids as antiemetics.
    Sensky T; Baldwin A; Pettingale KW
    Br Med J (Clin Res Ed); 1983 Mar; 286(6367):802. PubMed ID: 6297661
    [No Abstract]   [Full Text] [Related]  

  • 31. Characteristics, correlates, and assessment of psychosis in Parkinson disease without dementia.
    Barrett MJ; Smolkin ME; Flanigan JL; Shah BB; Harrison MB; Sperling SA
    Parkinsonism Relat Disord; 2017 Oct; 43():56-60. PubMed ID: 28735797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bath Salt-Induced Psychosis: Nursing Assessment, Diagnosis, Treatment, and Outcomes.
    Stiles BM; Fish AF; Cook CA; Silva V
    Perspect Psychiatr Care; 2016 Jan; 52(1):68-78. PubMed ID: 25624142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of hallucinations and psychosis in Parkinson's disease.
    Eng ML; Welty TE
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):316-30. PubMed ID: 20869621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
    Zoldan J; Friedberg G; Weizman A; Melamed E
    Adv Neurol; 1996; 69():541-4. PubMed ID: 8615178
    [No Abstract]   [Full Text] [Related]  

  • 35. A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: implications for the concept of cannabis psychosis.
    Boydell J; Dean K; Dutta R; Giouroukou E; Fearon P; Murray R
    Schizophr Res; 2007 Jul; 93(1-3):203-10. PubMed ID: 17462864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].
    Bailbé M; Karolewicz S; Neau JP; Dumas P; Gil R;
    Rev Neurol (Paris); 2002 Feb; 158(2):203-10. PubMed ID: 11965176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin.
    Mathis MV; Muoio BM; Andreason P; Avila AM; Farchione T; Atrakchi A; Temple RJ
    J Clin Psychiatry; 2017 Jun; 78(6):e668-e673. PubMed ID: 28493654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part II: comparison of behavioural effects of pulmonary versus parenteral cannabinoid exposure in rodents.
    Manwell LA; Ford B; Matthews BA; Heipel H; Mallet PE
    J Pharmacol Toxicol Methods; 2014; 70(1):112-9. PubMed ID: 24956154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rare presentation of intrathecal morphine withdrawal psychosis.
    Aiyer R; Jain V; Bhatia A; Mekinulov B; Gungor S
    Pain Manag; 2017 May; 7(3):171-173. PubMed ID: 28326948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cannabinoids and psychosis.
    D'Souza DC
    Int Rev Neurobiol; 2007; 78():289-326. PubMed ID: 17349865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.